Allergan Press Releases

CINCINNATI, April 15, 2019 /PRNewswire/ -- A new study by the University of Cincinnati Economics Center finds that the Ohio operations of biopharmaceutical company Allergan have a significant impact on the state's economy and communities. The study finds that the annual economic impact of Allergan's manufacturing and packaging facility in Cincinnati includes total output of $46.3 million and total earnings of $28.8 million. Allergan's economic impact is primarily a result of its daily operations and capital investments in Cincinnati, as well as its strong influence on employment in the community. The manufacturing facility, which employs nearly 200 highly skilled workers, supports 686 total jobs directly and indirectly through local investment and daily operations, according to the study. Additionally, Allergan's capital expenditures and operations in Cincinnati generate significant local and state tax revenues with a total fiscal impact of more than $1.3 million in 2017.

DUBLIN, April 15, 2019 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced that both leading independent proxy advisory firms, Institutional Shareholder Services Inc. ("ISS") and Glass Lewis & Co. ("Glass Lewis"), have recommended that the Company's shareholders vote FOR all of the Company's proposals and AGAINST the dissident shareholder proposal ("Proposal No. 6") calling for the immediate separation of Chair and CEO roles at the Company's 2019 Annual Meeting of Stockholders, to be held on May 1, 2019.

DUBLIN, April 10, 2019 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced that it has received the 2019 ENERGY STAR^® Partner of the Year Sustained Excellence Award for its continued leadership in energy management and efficiency. The U.S. Environmental Protection Agency award recognizes Allergan as an ENERGY STAR^® partner that has demonstrated exemplary commitment to energy leadership year over year. Allergan has a long history of promoting environmental responsibility within its global operations including through reducing greenhouse gas emissions and increasing use of renewable energy.

DUBLIN, April 9, 2019 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced it will release first quarter 2019 financial results on Tuesday, May 7, 2019, prior to the open of U.S. Financial Markets. Allergan will host a conference call and webcast at 8:30 a.m. Eastern Time on Tuesday, May 7, 2019 to discuss its financial results. The dial-in number to access the call is U.S./Canada (877) 251-7980, International (706) 643-1573, and the conference ID is 7466378.

DUBLIN, April 8, 2019 /PRNewswire/ -- Allergan plc (NYSE: AGN) today released the results of their first-of-its-kind worldwide medical aesthetics study, titled the Allergan 360° Aesthetics Report, exploring the mindset and motivations of aesthetically conscious consumers across a variety of ages, races, cultures and genders, as well as the physicians who treat them.  

DUBLIN, April 2, 2019 /PRNewswire/ -- Allergan plc, (NYSE: AGN), a leading global pharmaceutical company and Molecular Partners (SIX: MOLN), a clinical-stage biotechnology company developing a new class of drugs known as DARPin^® therapies, today announced topline safety results from MAPLE, a 28 week open-label study which enrolled 123 age-related Neovascular Macular Degeneration (nAMD) patients and evaluated the safety of abicipar produced via a modified manufacturing process. In this single arm study, treatment naïve or prior anti-VEGF treated patients received three monthly 2mg abicipar injections followed by 2mg injections every 8 weeks for up to a total of five injections through week 28.

DUBLIN, March 26, 2019 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced it has completed the acquisition of Envy Medical, Inc., a privately held company with proprietary technology in skin resurfacing. The acquisition enhances Allergan's best-in-class Medical Aesthetics portfolio with the addition of Envy's Dermalinfusion, a non-surgical, non-invasive skin resurfacing system for the face and body. Offered in physician's offices, medical spas and luxury spas, Dermalinfusion is the only treatment that simultaneously exfoliates, extracts and infuses the skin with professional strength serums, using medical grade diamond treatment tips. Each serum is specifically formulated to help treat a variety of skin concerns across all skin types.

DUBLIN, March 21, 2019 /PRNewswire-PRWeb/ -- CoolSculpting, owned by Allergan plc, is partnering once again with television personality on Bravo's "The Real Housewives of New York City", philanthropist and fashion lifestyle entrepreneur Sonja Morgan to help women prepare for warmer weather and banish their Bikini Denial this summer.

DUBLIN, March 20, 2019 /PRNewswire/ -- Television personality on Bravo's "The Real Housewives of New York City", philanthropist, fashion lifestyle entrepreneur and mom, Sonja Morgan, continues her partnership with CoolSculpting, owned by Allergan plc, to talk about "Bikini Denial." Bikini Denial identifies the feeling that many woman get when realizing that swimsuit season has snuck up on her and she is not prepared to bare it all at the beach or pool until she frees herself of stubborn fat. According to a recent survey, the most common area women feel self-conscious about is their belly¹. CoolSculpting is FDA-cleared to reduce fat in the abdomen area, along with eight other areas of the body, and can target that unwanted fat without surgery and little to no downtime.

DUBLIN, March 18, 2019 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the company's supplemental New Drug Application (sNDA) for AVYCAZ^® (ceftazidime and avibactam), expanding the label to include pediatric patients 3 months and older for the treatment of complicated intra-abdominal infections (cIAI) in combination with metronidazole and complicated urinary tract infections (cUTI). This is the first FDA approval of a pediatric indication for cUTI and cIAI in more than a decade.